b. PT/OT/SPL services performed, by a qualified clinician employed by a physician/NPP or physician/NPP group without a Medicare NPI should be reported to Medicare under the physicians/NPPs Medicare NPI, with an appropriate HCPCS/CPT code and the appropriate therapy modifier (GN, GO, GP).
ity.18,19 The Abl SH2 domain forms an extensive interaction interface with the C-terminal lobe of the kinase domain that is stabilized by an interlocking network of hydrogen bonds (Fig. 2).18 Due to the different relative orientation of the 2 kinase lobes in Src and Abl, the SH2 domain approaches the kinase domain much closer in Abl (Fig. 2). The SH2âC-
1 Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. 2  Cancer. 2014; 120(7):1002-1009.CR-ABL mutations may confer resistance by a variety of mechanisms, but commonly affect conformation of the protein TKI binding site on the tyrosine kinase phosphate binding loop (P-loop) or adenosine triphosphate (ATP) binding site such that protein TKI inactivation of tyrosine kinase is blocked.